In several papers it's been hypothesised that there is leakage in the BBB in PD patients and other neurodegenerative diseases (coming back to the notion that vascular issues underlie the causes of these diseases. But you're right, afa should not be able to cross the BBB because it isn't a cyclic peptide ie bremelanotide. I've been wondering what is the mode of action for treating PD if the drug can't get to where it's supposed to go? We know stroke can be treated outside the BBB by restoring the integrity of the BBB and reducing inflammation through vascular action. I just surmised that this might be how they intended to treat PD.
Ann: CLINUVEL Newsletter III - June 2024, page-30
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CUV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.37 |
Change
0.130(0.85%) |
Mkt cap ! $770.0M | |||
| Open | High | Low | Value | Volume |
| $15.36 | $15.54 | $15.18 | $1.274M | 82.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 237 | $15.31 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.50 | 282 | 2 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| CUV (ASX) Chart |